A 58-year-old womanwith calcinosis Raynaud esophageal sclerodactyly telangiectasia (CREST) syndrome presented with slowly progressive renal dysfunction. She was normotensive with normal plasma renin activity and lacking symptomsof vasculitis. Mild proteinuria was of tubular origin, but serological tests and an absence of sicca symptoms excluded the possibility of Sjogren's syndrome. Light microscopic study of renal biopsy showed interstitial fibrosis with ectasia and degeneration of proximal tubule and lymphocyteinfiltration. Therewereno remarkablechanges in the glomeruli. Chromatographic analysis of the Chinese herbs regimen that she had been taking for several years demonstrated aristolochic acid. She was diagnosed as Chinese herbs nephropathy. Therapy with oral prednisolone was markedly effective in improving renal function and anemia. To our knowledge, this is the first report of Chinese herbs nephropathy complicating connective tissue disease. It is important to consider the possibility of Chinese herbs nephropathy when patients treated with Chinese herbs develop renal dysfunction.
Introduction
Chinese herbs nephropathy (CHN) was first reported in Belgium by Vanherweghemand colleagues in 1993 (1) . It is characterized by rapidly progressive fibrosing interstitial nephritis without the involvement of glomerular lesions. Most patients with CHNin their series had received Chinese herbs as a slimmingregimen. Theactive chemical componentsof the Chinese herbs were analyzed in detail using high-performance liquid chromatography (HPLC) to clarify which component in the Chinese herbs caused nephritis (2) ; it was revealed that the Chinese herbs contained aristolochic acid (AA). AAhas been reported to be a chemical that can induce interstitial nephritis. Since then, an increasing number of cases with renal failure due to AAhave been reported in Taiwan (3) and Japan (4) . Wepresent here a case of CHNin a patient with calcinosis Raynaud esophageal sclerodactyly telangiectasia (CREST)syndrome and discuss the pathogenesis and treatment of CHN.
Case Report
A 58-year-old womanwith scleroderma was admitted to
AoyamaHospital, Tokyo Women's Medical University because of dyspnea on effort and renal dysfunction. She had noticed Raynaud's phenomenonat the age of 40. In 1985, she had started taking several kinds of Chinese herbs which were obtained from a pharmacy for edema of her hands and fingers. In 1986, she began attending an out-patient clinic for Chinese herbal medicine. While she continued to go to the clinic until 1999, the herbal formula was changed several times. She consulted our hospital in 1993 at 51 years of age, because of dyspnea on effort and palpitation. She was diagnosed as CREST syndrome, due to calcinosis of her finger tips, Raynaud's phenomenon, esophageal reflux, sclerodactylia, telangiectasia, and positive anti-centromere antibody. She had normal renal function from her first examination until June 1997, then serum creatinine levels started to increase gradually. homogeneous and discrete-speckled pattern) and anti-centromere antibody (147 IU/ml, determined by enzyme immunoassay) were positive. The other autoantibodies including antitopoisomerase I, anti-SSA, anti-SSB, anti-RNP and anti-Sm antibodies were negative. Schirmer and gumtests were negative. The patient was evaluated as not having the complication of Sjogren's syndrome. Plasma renin activity and angiotensin II were normal at 1.5 ng/ml/h and 24 mg/dl, respectively. Urine volume was 1 ,900 ml/day and 24-hour creatinine clearance was 22 ml/min. A 24-hour urine collection contained 450 mg of protein despite a negative albustix test, thereby suggesting that proteinuria was derived from tubular damage. Urinary P2 microglobulin was 16,746 |ig// (normal range: <200), and NAG was 6. 1 U// (normal range: <1 1.5). Ultrasonography revealed mildly atrophic kidneys. Renal biopsy contained a total of 13 glomeruli, of which 3 were totally sclerosed but other glomeruli were normal. In the interstitium, ectasia and degeneration of the proximal tubular cells and severe fibrotic changes with lymphocyte infiltration were seen focally ( Fig. 1 ). There was no evidence of vascular involvement suggesting angiitis or scleroderma renal crisis (SRC). Immuno-fluorescence staining was negative. Considering the prolonged clinical course and the laboratory and pathological findings, it was unlikely that SRC or angiitis was the cause of renal dysfunction. These results prompted us to assess the medicines this patient took as a cause of interstitial renal failure. After reviewing all the medicines she took, Chinese herbs were strongly suspected as the cause of renal failure. Recently, it has been reported that interstitial renal failure is induced by aristolochic acid contained in Chinese herbs. Since she had been taking a mixture of several Chinese herbs included in a single formula, we analyzed this Chinese herbs mixture. AA-I which is knownto be one of the causative agents of CHNwas detected by HPLC (Fig. 2) . Renal dysfunction and anemia had progressed gradually since February 1997, and continued to progress even after discontinuing all of the herbal medicines in September 1999. In the clinical course shownin 
Discussion
Renal dysfunction in the present case was diagnosed as CHN by renal histology and the presence of AA-I in the Chinese herbs the patient took. In general, the pathological examination of CHNis reported to reveal diffuse interstitial hypocellular fibrosis and tubular atrophy without any prominent glomerular disorder (1), which are similar findings to those of our case. AAdetected in the Chinese herbs formula is reported to be a causative agent of renal interstitial fibrosis (2). AAis usually contained in the Chinese herb "Kanmokutsu". The present patient received "Toki-shigyaku-ka-gosyuyu-syokyo-to", one of the traditional prescriptions of herbal mixtures. In Japan, the prescription contains "Mokutsu", which is Akebia quinata in Latin, and usually does not contain AAs. However, when "Tokishigyaku-ka-gosyuyu-syokyo-to" is prepared in China, it often contains "Kanmokutsu" (aristolochia manshuriensis) in place of "Mokutsu" and this herb contains AAs (5) . In the present case, the patient's family doctor imported the Chinese herbs directly from China. Weconsidered that "Kanmokutsu" might have been included in the "Toki-shigyaku-ka-gosyuyusyokyo-to" mixture made in China. In AAs,nine analogs from plants are well known. These are I (A), II, III, IV, C (III a), D (IV a) and E (6). AA-I in particular is reported to be a potent cause of gene mutation (6) Most reported patients with CHNshow rapid deterioration of renal function despite discontinuation of the herbal medications. Schmeiser and colleagues demonstrated the presence of AA-derived DNAadducts in the renal tissue of patients with CHN(7) and suggested that DNAmutation was responsible for the renal fibrotic process and urothelial cancers observed in CHN (3) . In the present case renal function showed progressive deterioration despite discontinuation of the herbal treatment as is typical of most patients with CHN.Wesuggested that mutations in the DNAlevel might be the reason why the progressive fibrotic changes persisted even though the exposure to AAshad stopped.
Carcinomas of the urinary tract are described in CHNwith increasing frequency (8). Cosyns and colleagues studied nineteen kidneys and ureters from 10 CHNpatients and demonstrated an overexpression of mutated p53 (a tumor suppressor gene) in all carcinoma in situ and papillary transitional cell carcinoma specimens examined (9) . There was no evidence of such malignancy in this case at the time of the study. However, it is important to be aware of this evidence and strict observation must be continued. The standard treatment of CHNhas not yet been established. In the present case, oral prednisolone was given and her renal function and anemia showedimprovement. Vanherweghemand colleagues reported the efficacy of corticosteroid therapy in Table 1 . Previous Case Reports of Chinese Herbs Nephropathy (CHN)
C: Cessation of herbal medications, CS: Corticosteroids, HD:Hemodialysis. group (n=12) to a control group (n=23). Renal function was better preserved in the steroid-treated group at one year (p=0.001). Only two of the 12 patients in the steroid-treated group required dialysis at one year compared with 16 of 23 patients in the control group. Therefore, Vanherweghemand colleagues suggested that steroid induces interference with T lymphocyte functions and the synthesis of chemical mediators might lead to suppression of production and proliferation of the extracellular matrix as a possible mechanism. They gave prednisolone at a dose of 1 mg/kgweight as an initial dose. Since our case wascomplicated by CRESTsyndrome, high-dose steroid therapy was considered a risk factor for scleroderma renal crisis. Therefore, we decided to administer 30 mg/day which was much less than the dose used in the previous study. The effective dosage of prednisolone for patients with CHNhas not yet been established. Comparisons of therapy and prognosis of several reports are shownin Table 1 . To our knowledge, there were few reports of successful treatment of CHNthat improved the prognosis. In this report, we demonstrated that the administration of corticosteroids mayhave improved the renal function of this CHNcase, suggesting that steroid-therapy would be a good strategy for CHN. Further investigation of the treatment including corticosteroids for CHNmust be undertaken in the future.
In this case, a diuretic Chinese herbal formula was prescribed for the edematous phase of skin thickening in CRESTsyndrome. In somecases of connective tissue diseases, especially slowly progressive cases, it is difficult to diagnose the disease from early symptoms. In fact, it is not rare for patients with connective tissue diseases taking Chinese herbal medications or somekinds of herbal tea since Chinese herbs are thought to be safe, and to have a lower incidence of adverse effects. The present case should serve to warn physicians of the importance of considering Chinese herbs as one of the possible causal factors promoting renal failure in patients with connective tissue diseases.
